Should I buy or sell Codexis stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CDXS shares. View CDXS analyst ratings or view top-rated stocks .

What is Codexis' stock price target for 2024?

6 Wall Street research analysts have issued 12 month price targets for Codexis' shares. Their CDXS share price targets range from $4.00 to $10.00. On average, they predict the company's share price to reach $7.17 in the next year. This suggests a possible upside of 190.1% from the stock's current price. View analysts price targets for CDXS or view top-rated stocks among Wall Street analysts .

How have CDXS shares performed in 2023?

Codexis' stock was trading at $4.66 at the beginning of the year. Since then, CDXS stock has decreased by 47.0% and is now trading at $2.47. View the best growth stocks for 2023 here .

Are investors shorting Codexis?

Codexis saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 3,110,000 shares, an increase of 12.3% from the October 31st total of 2,770,000 shares. Based on an average daily volume of 846,800 shares, the days-to-cover ratio is presently 3.7 days. View Codexis' Short Interest .

When is Codexis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our CDXS earnings forecast .

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) posted its earnings results on Thursday, November, 2nd. The biotechnology company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.06. The biotechnology company earned $9.28 million during the quarter, compared to analyst estimates of $10.96 million. Codexis had a negative trailing twelve-month return on equity of 53.16% and a negative net margin of 110.41%.

What ETFs hold Codexis' stock?

ETFs with the largest weight of Codexis (NASDAQ:CDXS) stock in their portfolio include Jacob Forward ETF (JFWD) , Invesco Nasdaq Future Gen 200 ETF (QQQS) and ARK Genomic Revolution ETF (ARKG) . Inspire Small/Mid Cap ETF (ISMD) .

What is John J. Nicols' approval rating as Codexis' CEO?

25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com . John J. Nicols has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD) , Sorrento Therapeutics (SRNE) , AbbVie (ABBV) , Micron Technology (MU) , Enphase Energy (ENPH) , Intellia Therapeutics (NTLA) , NVIDIA (NVDA) , OPKO Health (OPK) and Antares Pharma (ATRS) .

Who are Codexis' major shareholders?

Codexis' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (6.21%), Baillie Gifford & Co. (5.80%), Ameriprise Financial Inc. (2.56%), Assenagon Asset Management S.A. (2.51%), Jacobs Levy Equity Management Inc. (2.34%) and Federated Hermes Inc. (2.00%). Insiders that own company stock include Bernard J Kelley , Byron L Dorgan , Dennis P Wolf , John J Nicols , Kevin Norrett, Margaret Nell Fitzgerald, Patrick Y Yang , Sriram Ryali and Stephen George Dilly. View institutional ownership trends .

How do I buy shares of Codexis?

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Codexis Stock Price, News & Analysis (NASDAQ:CDXS)

$2.47

+0.11 (+4.66%)

(As of 12/1/2023 ET)

Compare

Today's Range: $2.20
▼
$2.49
50-Day Range: $1.50
▼
$2.47
52-Week Range: $1.45
▼
$6.98

Volume: 777,681 shs
Average Volume: 701,064 shs
Market Capitalization: $172.41 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.17

Codexis MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 190.1% Upside
$7.17 Price Target
Short Interest: Healthy
4.46% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -3.67
Upright™ Environmental Score
News Sentiment: 0.83
Based on 5 Articles This Week
Insider Trading: Acquiring Shares
$55,403 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.93) to ($0.64) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

350th out of 957 stocks

Industrial Organic Chemicals Industry

7th out of 17 stocks

3.3

Analyst's Opinion

Consensus Rating
Codexis has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.17, Codexis has a forecasted upside of 190.1% from its current price of $2.47.
Amount of Analyst Coverage
Codexis has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.46% of the outstanding shares of Codexis have been sold short.
Short Interest Ratio / Days to Cover
Codexis has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Codexis has recently increased by 12.27%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Codexis does not currently pay a dividend.
Dividend Growth
Codexis does not have a long track record of dividend growth.

2.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Codexis has received a 14.84% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Industrial enzymes for pharmaceuticals", "Biochemical assay kits", and "Medical technology engineering" products. See details.
Environmental Sustainability
The Environmental Impact score for Codexis is -3.67.

2.7

News and Social Media Coverage

News Sentiment
Codexis has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Codexis this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for CDXS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
1 people have added Codexis to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Codexis insiders have bought 31.29% more of their company's stock than they have sold. Specifically, they have bought $55,403.00 in company stock and sold $42,200.00 in company stock.
Percentage Held by Insiders
Only 6.30% of the stock of Codexis is held by insiders.
Percentage Held by Institutions
87.94% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Codexis are expected to grow in the coming year, from ($0.93) to ($0.64) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Codexis is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Codexis is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Codexis has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Codexis Stock (NASDAQ:CDXS)

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

CDXS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CDXS Stock News Headlines

November 30, 2023 | finance.yahoo.com

Codexis, Inc.'s (NASDAQ:CDXS) Intrinsic Value Is Potentially 92% Above Its Share Price

November 30, 2023 | americanbankingnews.com

Codexis (NASDAQ:CDXS) Share Price Crosses Above Two Hundred Day Moving Average of $2.28

December 3, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 28, 2023 | finance.yahoo.com

Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023

November 14, 2023 | finance.yahoo.com

Codexis to Participate in 35th Annual Piper Sandler Healthcare Conference

November 13, 2023 | finance.yahoo.com

Codexis, Inc. (NASDAQ:CDXS) is largely controlled by institutional shareholders who own 74% of the company

November 8, 2023 | msn.com

Benchmark Downgrades Codexis (CDXS)

November 3, 2023 | finance.yahoo.com

Q3 2023 Codexis Inc Earnings Call

December 3, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

November 3, 2023 | finance.yahoo.com

Codexis, Inc. (NASDAQ:CDXS) Q3 2023 Earnings Call Transcript

November 2, 2023 | finance.yahoo.com

Codexis Reports Third Quarter 2023 Financial Results

November 2, 2023 | finance.yahoo.com

Codexis Inc (CDXS) Reports Q3 2023 Financial Results: Net Loss of $34.9 Million

November 1, 2023 | markets.businessinsider.com

Codexis earnings: here's what Wall Street expects

October 26, 2023 | finance.yahoo.com

Codexis to Present Update on ECO Synthesis™ Platform at TIDES Europe

September 29, 2023 | finance.yahoo.com

Codexis CEO Stephen Dilly Wins Prestigious 2023 Bloom Burton Award

September 18, 2023 | finance.yahoo.com

Codexis CEO Stephen Dilly Named as Finalist of 2023 Bloom Burton Award

September 13, 2023 | marketwatch.com

Codexis Stock Climbs After Executives Buy Up Shares

September 13, 2023 | msn.com

Codexis shares up after CFO buys 11,650 shares

September 13, 2023 | finance.yahoo.com

Insider Buying: Kevin Norrett Acquires 9,000 Shares of Codexis Inc (CDXS)

September 12, 2023 | finance.yahoo.com

Codexis to Participate in Cantor Global Healthcare Conference

September 8, 2023 | bizjournals.com

Peninsula biotech grabs more space as it plans to take 2nd pneumonia vaccine into clinic

September 8, 2023 | msn.com

Codexis announces a San Carlos facility lease that could potentially save $30M

September 8, 2023 | finance.yahoo.com

Codexis Announces Agreement for Assignment and Assumption of San Carlos Facility Lease

September 2, 2023 | nasdaq.com

Benchmark Reiterates Codexis (CDXS) Buy Recommendation

August 14, 2023 | msn.com

Stifel Maintains Codexis (CDXS) Buy Recommendation

August 8, 2023 | finance.yahoo.com

BlackRock Inc. Acquires Significant Stake in Codexis Inc.

August 5, 2023 | fool.com

Codexis (NASDAQ: CDXS)

See More Headlines

Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 12/03/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/22/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Industrial organic chemicals
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:CDXS
CUSIP: 19200510
CIK: 1200375
Web: www.codexis.com
Phone: (650) 421-8100
Fax: 650-421-8102
Employees: 248
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.17
High Stock Price Target: $10.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +190.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-33,590,000.00
Net Margins: -110.41%
Pretax Margin: -110.15%
Return on Equity: -53.16%
Return on Assets: -31.17%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.68
Quick Ratio: 2.62

Sales & Book Value

Annual Sales: $138.59 million
Price / Sales: 1.24
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.31 per share
Price / Book: 1.89

Miscellaneous

Outstanding Shares: 69,800,000
Free Float: 65,403,000
Market Cap: $172.41 million
Optionable: Optionable
Beta: 1.86

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Stephen George Dilly MBBS (Age 63)
Ph.D., President, CEO & Director
Comp: $753.61k
Mr. Kevin Norrett M.B.A. (Age 50)
M.S., Chief Operating Officer
Comp: $507.28k
Ms. Margaret Fitzgerald J.D. (Age 52)
Chief Legal and Compliance Officer, General Counsel & Secretary
Comp: $300.03k
Mr. Sriram Ryali M.B.A. (Age 41)
Chief Financial Officer
Carrie McKim
Director of Investor Relations
Ms. Karen Frechou-Armijo
Senior VP & Head of Human Resources
Dr. Stefan Lutz Ph.D.
Senior Vice President of Research
Mr. Robert Sato M.B.A.
Ph.D., Senior Vice President of Pharmaceutical Development, Quality & Regulatory

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CDXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Codexis stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CDXS shares.
View CDXS analyst ratings or view top-rated stocks.
What is Codexis' stock price target for 2024?: 6 Wall Street research analysts have issued 12 month price targets for Codexis' shares. Their CDXS share price targets range from $4.00 to $10.00. On average, they predict the company's share price to reach $7.17 in the next year. This suggests a possible upside of 190.1% from the stock's current price.
View analysts price targets for CDXS or view top-rated stocks among Wall Street analysts.
How have CDXS shares performed in 2023?: Codexis' stock was trading at $4.66 at the beginning of the year. Since then, CDXS stock has decreased by 47.0% and is now trading at $2.47.
View the best growth stocks for 2023 here.
Are investors shorting Codexis?: Codexis saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 3,110,000 shares, an increase of 12.3% from the October 31st total of 2,770,000 shares. Based on an average daily volume of 846,800 shares, the days-to-cover ratio is presently 3.7 days.
View Codexis' Short Interest.
When is Codexis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our CDXS earnings forecast.
How were Codexis' earnings last quarter?: Codexis, Inc. (NASDAQ:CDXS) posted its earnings results on Thursday, November, 2nd. The biotechnology company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.06. The biotechnology company earned $9.28 million during the quarter, compared to analyst estimates of $10.96 million. Codexis had a negative trailing twelve-month return on equity of 53.16% and a negative net margin of 110.41%.

What ETFs hold Codexis' stock?: ETFs with the largest weight of Codexis (NASDAQ:CDXS) stock in their portfolio include Jacob Forward ETF (JFWD), Invesco Nasdaq Future Gen 200 ETF (QQQS) and ARK Genomic Revolution ETF (ARKG).Inspire Small/Mid Cap ETF (ISMD).
What is John J. Nicols' approval rating as Codexis' CEO?: 25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees.
What other stocks do shareholders of Codexis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).
Who are Codexis' major shareholders?: Codexis' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (6.21%), Baillie Gifford & Co. (5.80%), Ameriprise Financial Inc. (2.56%), Assenagon Asset Management S.A. (2.51%), Jacobs Levy Equity Management Inc. (2.34%) and Federated Hermes Inc. (2.00%). Insiders that own company stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Kevin Norrett, Margaret Nell Fitzgerald, Patrick Y Yang, Sriram Ryali and Stephen George Dilly.
View institutional ownership trends.
How do I buy shares of Codexis?: Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CDXS) was last updated on 12/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial